Insider and Congress filings

AstraZeneca PLC (AZN)

Drug Manufacturers, listed on NYSE.

13 insider transactions46 Congress tradeslast filed Nov 10, 2026

Share
Download on the App StoreGet it on Google Play

Free on iOS and Android

Scan to get
the app

GetSignal NewsCompany release · Nov 10, 2026

AstraZeneca grants $1.6 million to US nonprofits for healthcare access

The grants go to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative.

Written by GetSignal with AI from SEC filings and the company’s own press releases; each article links to its source. Not investment advice.

Read the article

EarningsQ3 FY2026 · reported Oct 30, 2026

Q3 FY2026: Beat on EPS. Revenue came in line. Next report Feb 9, 2027.

EPS Q3 FY2026

Reported$2.79
Consensus$2.60

Revenue Q3 FY2026

Reported$16.2B
Consensus$16.0B

Beat 3In line 3

Consensus $2.32 a share on $16.6B of revenue, the analysts’ forecast.

Every quarter

Money managers13F filings for Jun 30, 2026

5

of the 97 fund managers GetSignal tracks list AstraZeneca among their largest positions. Holocene Advisors held the most, $460.7M.

Tracked managers’ Q2 2026 moves

Vestal Pointadded+$66.4M
OrbiMedadded+$45.9M

Each manager’s 13F against the one before, priced at the Jun 30, 2026 close: an estimate, from each manager’s 15 largest moves. Not investment advice.

Every manager

Insider tradesForm 4 · 1 open-market filing shown

One open-market sale.

A median 2 business days from trade to filing. Form 4 is due within two.

Every filing
Companyfrom the company's filings and listing, as of Nov 14, 2026

About AstraZeneca PLC

Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Chief executive
Pascal Claude Roland Soriot
Employees
96,100
Listed since
May 12, 1993
Market value
$286.1B
Price to earnings (12 mo)
25.9
Net income per share, as reported (12 mo)
$7.12
Dividend yield
1.71%

www.astrazeneca.com

GetSignal News4 articles · newest first

GetSignal News

HeadlineSourceDate
AstraZeneca grants $1.6 million to US nonprofits for healthcare accessThe grants go to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative.Company releaseNov 10, 2026
AstraZeneca launches Meet Your Mark campaign on cancer biomarker testingFeaturing actor Mark-Paul Gosselaar, the campaign encourages people to ask about biomarker testing if they or a loved one is diagnosed with cancer.Company releaseOct 28, 2026
AstraZeneca makes ZEGFROVY available in US for certain lung cancersThe indication covers adults with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.Company releaseOct 22, 2026
AstraZeneca opens new global R&D center in Kendall Square, CambridgeThe center builds on AstraZeneca's existing presence in Cambridge and Boston and places its scientists in a life sciences ecosystem.Company releaseOct 5, 2026

Written by GetSignal with AI from SEC filings and the company's own press releases; each article links to its source. Not investment advice.

Company news from every company we cover

Earnings6 reported quarters · next on Feb 9, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q3 FY2026reported Oct 30, 2026$2.79$2.60$16.2B$16.0BEPS beatRevenue in line
Q2 FY2026reported Jul 27, 2026$2.63$2.50$15.4B$15.4BEPS beatRevenue in line
Q1 FY2026reported Apr 29, 2026$2.58$2.57$15.3B$14.9BEPS in lineRevenue beat
Q4 FY2025reported Feb 10, 2026$2.12$2.09$15.5B$15.4BEPS in lineRevenue in line
Q3 FY2025reported Nov 6, 2025$2.38$2.28$15.2B$14.8BEPS beatRevenue beat
Q2 FY2025reported Jul 29, 2025$2.18$2.18$14.5B$14.1BEPS in lineRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

No earnings call briefs on AZN yet. Briefs from every company we cover.

13F filings13F positions as of Sep 30, 2026

Institutional holders

1,205 institutions reported AstraZeneca shares in 13F filings for Sep 30, 2026.
HolderValueSharesShares vs prior qtr% of shares out
Vanguard Capital Management LLC$7.4B45,656,840+0.6%2.94%
Capital World Investors$5.1B31,088,437+3.4%2.00%
FMR LLC$4.8B29,383,096+1.7%1.89%
Franklin Templeton Inc$3.6B19,051,066+15.4%1.23%
Vanguard Asset Management, Ltd$3.1B19,117,048+2.2%1.23%
JPMorgan Chase & Co.$3.0B18,428,214-4.0%1.19%
Primecap Management Co$2.9B18,108,546+0.1%1.17%
Amundi$2.8B17,121,350+4.3%1.10%
Capital International Investors$2.6B15,885,065-54.1%1.02%
Vanguard Fiduciary Trust Co$2.2B13,520,146+1.7%0.87%
Mirabaud Asset Management Ltd$2.1B12,474,000+98360.8%0.80%
Fisher Asset Management, LLC$1.9B11,501,748+3.2%0.74%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Sep 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

13F filings5 managers

Tracked fund managers holding AZN

ManagerValueSharesShare of book
Holocene Advisors$460.7M2,429,3491.0%
OrbiMed$171.1M915,7003.2%
Farallon Capital$108.8M574,0000.5%
Vestal Point Capital$85.3M450,0002.0%
Glenview CapitalLarry Robbins$34.9M184,2790.6%

5 of the 97 fund managers we track list AZN shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.

Form 41 filing shown · newest filing first

Open-market insider trades

InsiderActionSharesPriceValueTrade dateDelay
(business days)
Mani SharmaSold11,893$185.78$2.2MMay 20, 2026filed May 22, 20262d

One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.

Other Form 4 activity (10)
InsiderEventSharesDate
Mani SharmaStock award1Nov 6, 2026
Mani SharmaStock award2Oct 6, 2026
Mani SharmaStock award1Sep 8, 2026
Mani SharmaOther (see filing)20Aug 8, 2026
Mani SharmaSVP, Group ControllerStock award2Aug 6, 2026
Mani SharmaStock award2Jul 6, 2026
Mani SharmaStock award1Jun 8, 2026
Mani SharmaStock award1Apr 7, 2026
Mani SharmaStock award1May 6, 2026
Mani SharmaOther Form 4 entry (see filing)3,028Mar 18, 2026

Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.

STOCK Act20 disclosures of 46 on record · median 26d of the 45 allowed

Congress trades in AZN

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Alan ArmstrongSelfStockPurchase$15,001 - $50,000-4.9% since the tradeEstimated entry price $193.88, close on Mon Mar 30Current price $184.45, close on Fri Nov 13Mar 30, 2026Jul 21, 2026113d
Alan ArmstrongSelfStockPurchase$1,001 - $15,000-6.5% since the tradeEstimated entry price $197.22, close on Tue Mar 31Current price $184.45, close on Fri Nov 13Mar 31, 2026Jul 21, 2026112d
Ro KhannaStockPurchase$1,001 - $15,000-2.9% since the tradeEstimated entry price $189.90, close on Fri Mar 13Current price $184.45, close on Fri Nov 13Mar 13, 2026Apr 7, 202625d
Ro KhannaStockSale$15,001 - $50,000-10.3% since the saleEstimated exit price $205.55, close on Fri Feb 13Current price $184.45, close on Fri Nov 13Feb 13, 2026Mar 9, 202624d
Julia LetlowStockPurchase$1,001 - $15,000+1.9% since the tradeEstimated entry price $90.47, close on Mon Dec 8, 2025$180.94 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Dec 8, 2025Jan 13, 202636d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000+2.2% since the tradeEstimated entry price $90.27, close on Thu Dec 18, 2025$180.54 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Dec 18, 2025Jan 12, 202625d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000+2.6% since the tradeEstimated entry price $89.91, close on Wed Nov 19, 2025$179.82 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Nov 19, 2025Dec 15, 202526d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+12.0% since the tradeEstimated entry price $82.34, close on Thu Oct 30, 2025$164.68 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+12.0% since the saleEstimated exit price $82.34, close on Thu Oct 30, 2025$164.68 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Oct 30, 2025Nov 21, 202522d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+11.9% since the saleEstimated exit price $82.40, close on Fri Oct 31, 2025$164.80 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Oct 31, 2025Nov 21, 202521d
Gilbert Ray Cisneros, Jr.StockPurchase$1,001 - $15,000+9.6% since the tradeEstimated entry price $84.14, close on Tue Oct 21, 2025$168.28 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Oct 21, 2025Nov 18, 202528d
Val T. HoyleSpouseStockSale$1,001 - $15,000+22.4% since the saleEstimated exit price $75.37, close on Tue Sep 23, 2025$150.74 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Sep 23, 2025Oct 10, 202517d
Val T. HoyleSpouseStockPurchase$1,001 - $15,000+23.2% since the tradeEstimated entry price $74.83, close on Tue Oct 29, 2024$149.66 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Oct 29, 2024Sep 12, 2025318d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+25.9% since the tradeEstimated entry price $73.26, close on Mon Jun 9, 2025$146.52 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Jun 9, 2025Aug 13, 202565d
Lisa C. McClainSpouseStockSale$1,001 - $15,000+30.8% since the saleEstimated exit price $70.49, close on Tue Jun 17, 2025$140.98 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Jun 17, 2025Aug 13, 202557d
Lisa C. McClainSpouseStockPurchase$1,001 - $15,000+30.0% since the tradeEstimated entry price $70.95, close on Tue Jul 22, 2025$141.90 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Jul 22, 2025Aug 13, 202522d
Bruce WestermanStockSale$1,001 - $15,000+39.3% since the saleEstimated exit price $66.19, close on Mon Apr 21, 2025$132.38 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Apr 21, 2025May 12, 202521d
Bruce WestermanStockPurchase$1,001 - $15,000+22.0% since the tradeEstimated entry price $75.58, close on Mon Mar 3, 2025$151.16 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Mar 3, 2025Apr 16, 202544d
Ro KhannaStockPurchase$1,001 - $15,000+37.0% since the tradeEstimated entry price $67.33, close on Fri Oct 13, 2023$134.66 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Oct 13, 2023Nov 8, 202326d
Michael T. McCaulStockSale$50,001 - $100,000+28.8% since the saleEstimated exit price $71.60, close on Mon Aug 14, 2023$143.20 in today's shares after a 1-for-2 reverse split; the move runs from this priceCurrent price $184.45, close on Fri Nov 13Aug 14, 2023Sep 14, 202331d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in AZN filterable by party, chamber, type and account.

STOCK Act5 members · estimate, as of Nov 14, 2026

Members of Congress reporting a position

5 members report a position of $1,000 or more (estimated).
MemberParty, chamberEstimated positionShare of their portfolio
Lucy McBathDemocrat · House$15,001 - $50,0000.3%
Mark HarrisRepublican · House$15,001 - $50,0000.8%
Julia LetlowRepublican · House$1,001 - $15,0000.8%
Cliff BentzRepublican · House$1,001 - $15,0000.5%
Gilbert Ray Cisneros, Jr.Democrat · House$1,001 - $15,000<0.1%

A further member reports a position estimated under $1,000; that member is not listed.

The largest estimated position is in the $15,001 - $50,000 band. Estimate, as of Nov 14, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 16, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on AZN show and how current they are.

Are insiders buying or selling AZN?

Across the one open-market filing shown here, 0 were purchases and 1 was a sale.

Which members of Congress have traded AZN?

Alan Armstrong, Ro Khanna, Julia Letlow, Gilbert Ray Cisneros, Jr., Lisa C. McClain, Val T. Hoyle and others disclosed AZN transactions in the filings shown here.

Which members of Congress hold AZN?

5 members of Congress report a position of $1,000 or more in AZN in the estimate we hold as of Nov 14, 2026. The two largest estimated positions belong to Lucy McBath and Mark Harris; Julia Letlow holds one of the next largest, in the $1,001 - $15,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.

How quickly are AZN trades disclosed?

Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 26 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members

See every company we track